Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Acq. announced

ZEVRA THERAPEUTICS, INC. (KMPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/11/2023 EFFECT Form EFFECT - Notice of Effectiveness:
10/10/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
10/10/2023 8-K Quarterly results
10/10/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/06/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
09/28/2023 S-4 Form S-4 - Registration of securities, business combinations:
08/25/2023 4 Anderson Thomas (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 58,800 options to buy @ $0
08/24/2023 3 Anderson Thomas (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC.
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Investor presentation
Docs: " ",
" "
08/07/2023 8-K Appointed a new director
06/30/2023 4 Schafer Joshua (CCO & EVP, Bus. Development) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Bought 1,000 shares @ $5.4157, valued at $5.4k
06/02/2023 4 FAVORITO TAMARA A (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 10,000 options to buy @ $0
05/31/2023 4 Watton Corey Michael (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Bought 400 shares @ $5.1053, valued at $2k
05/19/2023 4 Bode John B (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Bought 1,390 shares @ $5.035, valued at $7k
Bought 300 shares @ $5.0391, valued at $1.5k
Bought 1,000 shares @ $5.0399, valued at $5k
Bought 4,759 shares @ $5.04, valued at $24k
Bought 100 shares @ $5.045, valued at $504.5
Bought 2,451 shares @ $5.05, valued at $12.4k
05/18/2023 4 Clifton R. LaDuane (CFO, Secretary & Treasurer) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Bought 51 shares @ $4.94, valued at $251.9
Bought 2,000 shares @ $4.9499, valued at $9.9k
Bought 689 shares @ $4.9495, valued at $3.4k
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 4 Calder Douglas W (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 58,800 options to buy @ $0
05/11/2023 3 Calder Douglas W (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC.
05/08/2023 4 Watton Corey Michael (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 58,800 options to buy @ $0
05/08/2023 4 Saluri Joseph (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 39,200 options to buy @ $0
05/08/2023 4 Plooster Matthew R (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 49,200 options to buy @ $0
05/08/2023 4 FAVORITO TAMARA A (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 39,200 options to buy @ $0
05/08/2023 4 DIXON WENDY L (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 22,500 options to buy @ $0
Granted 36,300 options to buy @ $0
05/08/2023 4 Bode John B (Director) has filed a Form 4 on ZEVRA THERAPEUTICS, INC.
Txns: Granted 58,800 options to buy @ $0
05/08/2023 3 Watton Corey Michael (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC.
05/08/2023 3 DIXON WENDY L (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC.
05/08/2023 3 Bode John B (Director) has filed a Form 3 on ZEVRA THERAPEUTICS, INC.
05/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Transition Agreement, between Zevra Therapeutics, Inc. and Richard W. Pascoe"
04/26/2023 8-K Quarterly results
04/17/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/30/2023 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy